Spectral Medical Announces Opening of Tigris Clinical Trial Site at the Mayo Clinic | Markets Insider
Spectral Medical Inc. announced the Mayo Clinic as its 19th site for the Tigris trial, a Phase 3 study on PMX treatment for endotoxemia and septic shock. Spectral is advancing PMX, a therapeutic device for septic shock, with FDA Breakthrough Device Designation. PMX is approved in Japan and Europe, used on over 340,000 patients.
Reference News
Spectral Medical Announces Opening of Tigris Clinical Trial Site at the Mayo Clinic | Markets Insider
Spectral Medical Inc. announced the Mayo Clinic as its 19th site for the Tigris trial, a Phase 3 study on PMX treatment for endotoxemia and septic shock. Spectral is advancing PMX, a therapeutic device for septic shock, with FDA Breakthrough Device Designation. PMX is approved in Japan and Europe, used on over 340,000 patients.